See composition in Appendix.
Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV–HCV co-infected patients: ANRS Co13 Hepavih, France, 2006–2008
Article first published online: 30 NOV 2009
© 2009 Blackwell Publishing Ltd
Journal of Viral Hepatitis
Volume 17, Issue 9, pages 650–660, September 2010
How to Cite
Michel, L., Villes, V., Dabis, F., Spire, B., Winnock, M., Loko, M.-A., Poizot-Martin, I., Valantin, M. A., Bonnard, P., Salmon-Céron, D., Carrieri, M. P. and and the ANRS Co13 HEPAVIH Study Group (2010), Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV–HCV co-infected patients: ANRS Co13 Hepavih, France, 2006–2008. Journal of Viral Hepatitis, 17: 650–660. doi: 10.1111/j.1365-2893.2009.01223.x
- Issue published online: 4 AUG 2010
- Article first published online: 30 NOV 2009
- Received June 2009; accepted for publication September 2009
- hepatitis C;
- quality of life
Summary. Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV–HCV co-infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co-infected patients, even those at an advanced stage of disease. The analysis was conducted on enrolment data of 328 HIV–HCV co-infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self-administered questionnaires which included items on socio-behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES-D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count <200 per mm3 was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P < 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P < 0.001) of the impact of fatigue was found across the categories ‘DS/TDS’, ‘DS/no TDS’, ‘no DS/TDS’ and ‘no DS/no TDS’. Despite limitations related to the cross-sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV–HCV co-infected patients and relieve the burden of their dual infection.